Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CLVS

Clovis Oncology (CLVS) Stock Price, News & Analysis

Clovis Oncology logo

About Clovis Oncology Stock (NASDAQ:CLVS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.08
$1.09
52-Week Range
N/A
Volume
1.16 million shs
Average Volume
8.88 million shs
Market Capitalization
$11.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Stock News Headlines

Clovis Chamber names new Retail Rockstar
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Cancer Horoscope
See More Headlines

CLVS Stock Analysis - Frequently Asked Questions

Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to analyst estimates of $38.73 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Clovis Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY), NIO (NIO) and Micron Technology (MU).

Company Calendar

Last Earnings
11/03/2021
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CLVS
CIK
1466301
Employees
N/A
Year Founded
2009

Profitability

EPS (Trailing Twelve Months)
($1.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$264.52 million
Net Margins
-189.37%
Pretax Margin
-189.68%
Return on Equity
N/A
Return on Assets
-57.78%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.14
Quick Ratio
0.12

Sales & Book Value

Annual Sales
$148.76 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.15) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
144,955,000
Free Float
138,577,000
Market Cap
$11.60 million
Optionable
Optionable
Beta
0.24

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CLVS) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners